Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

American Journal of Hematology

Volumn 87, Issue 7, 2012, Pages 687-691

  Jabbour, Elias J ^a   Kantarjian, Hagop ^a   Eliasson, Lina ^b   Megan Cornelison, A ^a   Marin, David ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; COMMUNICATION SKILL; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ANTINEOPLASTIC AGENTS; DRUG COSTS; DRUG MONITORING; HEALTH CARE COSTS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84862555569     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23180     Document Type: Review

References (25)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at:. Accessed October 11, 2011.
2. Robin M, Guardiola P, Devergie A, et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005; 19: 1613-1620.
3. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
4. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009; 114: 1126.
5. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388.
6. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009; 113: 5401-5411.
7. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733-3736.
8. Sabaté E, editor. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. Available at:. Accessed October 11, 2011.
9. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: A meta-analysis. Med Care 2002; 40: 794-811.
10. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530.
11. Munakata J, Benner JS, Becker S, et al. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care 2006; 44: 893-899.
12. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86: 202-210.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
14. Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients: An overview of instruments developed to date. Pharmacoeconomics 2007; 25: 269-286.
15. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481-496.
16. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61-69.
17. St Charles M, Bollu VK, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114: 2209.
18. Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010; 26: 2861-2869.
19. O'Dwyer M, Atallah E. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol 2009; 46(2 Suppl 3): S16-S21.
20. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86: 471-474.
21. Williams LA, Ault P, Cleeland CS, et al. Symptom burden in chronic myeloid leukemia (CML). J Clin Oncol (ASCO Annual Meeting Proceedings) 2010; 28(Suppl 1): 6133.
22. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011; 35: 626-630.
23. Guilhot F, Coombs J, Zernovak O, et al. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). Blood (ASH Annual Meeting Abstracts) 2010; 116: 1514.
24. Nunes V, Neilson J, O'Flynn N, et al. Clinical guidelines and evidence review for medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2009. Available at:. Accessed October 11, 2011.
25. NCCN. (2011). National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2. Available at:. Accessed October 11, 2011. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia V.2.2012. © 2011 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.